These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7473080)

  • 1. Comparison of some control strategies for three-compartment PK/PD models.
    Hu C; Lovejoy WS; Shafer SL
    J Pharmacokinet Biopharm; 1994 Dec; 22(6):525-50. PubMed ID: 7473080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An efficient control strategy for dosage regimens.
    Hu C; Lovejoy WS; Shafer SL
    J Pharmacokinet Biopharm; 1994 Feb; 22(1):73-94. PubMed ID: 8027950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic model for educational simulations.
    van Meurs WL; Nikkelen E; Good ML
    IEEE Trans Biomed Eng; 1998 May; 45(5):582-90. PubMed ID: 9581056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors.
    Hughes JH; Keizer RJ
    CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1150-1160. PubMed ID: 34270885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.
    Lyons MA; Lenaerts AJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):375-89. PubMed ID: 26026426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.
    Volz AK; Krause A; Haefeli WE; Dingemanse J; Lehr T
    Clin Pharmacokinet; 2017 Dec; 56(12):1499-1511. PubMed ID: 28401480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian approach for PK/PD modeling with PD data below limit of quantification.
    Zhou H; Hartford A; Tsai K
    J Biopharm Stat; 2012; 22(6):1220-43. PubMed ID: 23075019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling.
    van den Brink WJ; Wong YC; Gülave B; van der Graaf PH; de Lange EC
    AAPS J; 2017 Jan; 19(1):274-285. PubMed ID: 27785749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect-Site Target-Controlled Infusion in the Obese: Model Derivation and Performance Assessment.
    Cortínez LI; Sepúlveda P; Rolle A; Cottin P; Guerrini A; Anderson BJ
    Anesth Analg; 2018 Oct; 127(4):865-872. PubMed ID: 29401079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?
    Tod MM; Padoin C; Petitjean O
    Clin Pharmacokinet; 2001; 40(11):803-14. PubMed ID: 11735603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics.
    Dodds MG; Vicini P
    Ann Biomed Eng; 2004 Sep; 32(9):1300-13. PubMed ID: 15493516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.
    Zhang L; Beal SL; Sheinerz LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):405-16. PubMed ID: 15000422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression.
    Kathman SJ; Williams DH; Hodge JP; Dar M
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):469-76. PubMed ID: 18443793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
    Miyazaki M; Sawada S; Nishide T; Iwanaga K; Morimoto K; Kakemi M
    Biol Pharm Bull; 2000 Jan; 23(1):87-96. PubMed ID: 10706418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
    Hashimoto Y; Sheiner LB
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.